At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2
At its R&D Day in London today, Gubra provided updates on obesity assets licensed to AbbVie and Boehringer Ingelheim, as well as highlighted its lead internal program UCN2
AI 導讀
CEO Markus Rohrwild and CDMO Thomas Langenickel provide an update on the company's peptide based drug development side, as well as venture and CRO arms.
🎙️
Podcast 專家音訊節目
收錄於 888news Podcast 智庫專區，包含精華摘要與上市公司即時行情
正文 · AI 翻譯
執行長 Markus Rohrwild 與 CDMO Thomas Langenickel 提供公司以肽為基礎的藥物開發部門、創投與 CRO 部門的最新進展。
來源： BiotechTV - News (podcasters.spotify.com)
開啟原文